IDiyas

For the Inventor, By the Inventor

Hayward, CA, United States of America

Jeremy Francis McRae

USPTO Granted Patents = 9 

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 52(Granted Patents)


Company Filing History:

goldMedal9 out of 1,095 
 
Illumina Corporation
 patents

Years Active: 2019-2024

Loading Chart...
9 patents (USPTO):
1. 12165742 - Splicing site classification using neural networks (2024-12-10),
2. 11837324 - Deep learning-based aberrant splicing detection (2023-12-05),
3. 11798650 - Semi-supervised learning for training an ensemble of deep convolutional neural networks (2023-10-24),
4. 11488009 - Deep learning-based splice site classification (2022-11-01),
5. 11397889 - Aberrant splicing detection using convolutional neural networks (CNNs) (2022-07-26),
6. 11386324 - Recurrent neural network-based variant pathogenicity classifier (2022-07-12),
7. 11315016 - Deep convolutional neural networks for variant classification (2022-04-26),
8. 10558915 - Deep learning-based techniques for training deep convolutional neural networks (2020-02-11),
9. 10423861 - Deep learning-based techniques for training deep convolutional neural networks (2019-09-24),

Title: The Innovative Journey of Jeremy Francis McRae

Introduction: Jeremy Francis McRae, an accomplished inventor based in Hayward, California, has made significant contributions to the field of biotechnology through his groundbreaking work. With a total of nine patents to his name, McRae's innovative spirit and technical expertise have positioned him as a prominent figure in the industry.

Latest Patents: Among his latest inventions, McRae has developed a remarkable technology for splice site classification using neural networks. This invention focuses on splice site prediction and aberrant splicing detection, utilizing a convolutional neural network (CNN) trained on various splice site examples. The CNN evaluates input sequences of nucleotides, providing classification scores that indicate the likelihood of each target nucleotide being a donor or acceptor splice site, or a non-splicing site.

Additionally, McRae's work on deep learning-based aberrant splicing detection showcases his expertise in creating convolutional neural network-based classifiers for variant classification. This technology employs a backpropagation-based gradient update technique, which aligns the CNN's outputs with ground truth labels. The classifier is constructed with groups of residual blocks, optimizing the convolution filters and window sizes for enhanced performance on benign and pathogenic training examples.

Career Highlights: McRae currently works at Illumina Corporation, where his research and innovations continue to advance the capabilities of genetic analysis and diagnostic technologies. His nine patents reflect his dedication to pushing the boundaries of research in this critical field.

Collaborations: Throughout his career, McRae has collaborated with renowned colleagues such as Kai-How Farh and Hong Gao. These partnerships have facilitated the exchange of ideas and expertise, fostering an environment of innovative research and development.

Conclusion: Jeremy Francis McRae's contributions to biotechnology exemplify the impact of innovative thinking in addressing complex scientific challenges. Through his cutting-edge patents and collaborations, he continues to pave the way for advancements in splice site prediction and variant classification, making significant strides in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…